Press Release

Revital Healthcare EPZ Ltd. Achieves WHO Prequalification for Early-Activation Auto-Disable Syringe: A Milestone for African Manufacturing and Immunization Programming

Revital Healthcare EPZ Ltd. stands as the exclusive African manufacturer granted WHO PQ status for their early activation auto-disable (AD) syringe.

Official Press Release

Mombasa, Kenya – [26th September 2023] – Revital Healthcare EPZ Ltd., a leader in African medical device manufacturing, announces a historic milestone in African manufacturing excellence. The company is the first to be granted Pre-Qualification (PQ) status by the World Health Organization (WHO) on July 11, 2023 for their early activation auto-disable (AD) syringe in Africa. This marks Revital’s more than ten-year commitment to injection safety in immunization programming across Africa.

The early-activation feature is the gold standard for safety in Immunization programs as preferred by UNICEF, and renders the syringe disabled at the start of administering and injection. Historically, the introduction of these devices have resulted in substantial reductions in rates of blood-borne infections such as HIV in immunization programs across Africa.

There are currently eight manufacturers who have WHO PQ status for this product, however Revital’s is the first and only to be produced in Africa. This is expected to decrease average syringe transport times by up to 80-90% for Africa, critical for rapid outbreak response and timely immunization campaigns.

Roneek Vora, Director of Marketing and Sales for Revital Healthcare EPZ Ltd., comments, “Revital’s historic WHO pre-qualification for the early-activation AD syringe exemplifies the transformative power of African innovation and manufacturing excellence. Our commitment to the well-being of our fellow people, especially children receiving life-saving immunization, is our motivation to continue to progress.”

Revital will be able to produce upwards of 300 million AD syringes per year.

This work was made possible through a grant from the Bill & Melinda Gates Foundation. In addition to supporting the development of this product to increase supply security for Africa, this helped create more than 200 new local jobs in Kilifi County, 80% of which are staffed by women in support of a joint commitment to gender equality.

“As the first African manufacturer to be approved by WHO to produce early activation auto-disable syringes, Revital is paving the way to expand local production of syringes,” said Violaine Mitchell, Director of Immunization at the Bill & Melinda Gates Foundation.

“We are proud to support Revital’s efforts to sustainably expand the supply of these syringes in Africa and ensure vaccines are delivered safely and quickly across the continent.”

The WHO PQ listing for the 0.5ml early-activation AD syringe can be accessed through the WHO Vaccine Quality Catalogue.

1st

First African Manufacturer

Revital is the sole African producer to hold WHO PQ status for their early activation auto-disable (AD) syringe.

Impact and Innovation

Revital’s achievement reflects African innovation and commitment to immunization safety and supply security

Enhanced Syringe Safety

The early-activation feature in Revital’s syringe sets a gold standard, reducing blood-borne infections in immunization programs.

Impact

Impact On Global Healthcare

Tamper-Proof

Impossible to alter or tamper

Enhanced Safety

Reduces blood-borne infection risk

Reduced Medical Waste

Reduces medical waste and associated disposal costs

Infection Prevention

Reduces the transmission of  HIV and hepatitis

Precision Dosage

Delivers precise and consistent dosages

Improved Immunization

Reliable delivery of vaccines

Reduced Contamination

One-time use iminimizes contamination risk

Quality Control

Stringent quality control measures

User-Friendly Design

Easy to handle and administer medications

Have Any Questions?

Manufacturing Capacity Annually

%

Women Employment

New Jobs Generated

Manufacturing Capacity Annually

%

Women Employment

New jobs generated

FAQ’s

Gain a better understanding of Revital’s early activation auto-disable (AD) syringes with these frequently asked questions.
What is Revital's early activation auto-disable (AD) syringe?
Revital’s AD Early Activation Syringe is designed to disable at the start of injection to ensure enhanced safety by stopping the chance of re-use.
Why is Revital's AD syringes important in healthcare?
Revital’s AD syringes play a crucial role in reducing the risk of blood-borne infections, enhancing injection safety, and preventing medication errors.
How will Revital's AD syringes improve immunization programs?
Revital’s AD syringes ensure precise dosing, prevent needle reuse, and reduce contamination, leading to safer and more effective immunization campaigns.
Is Revital's AD syringe compatible with different medications and vaccines?
Yes, Revital’s AD syringes are designed to be compatible with a wide range of medications and vaccines, making them versatile for various healthcare applications.
What are the environmental benefits of Revital's AD syringes?
Revitals AD Syringe requires less plastic during the manufacturing process and hence generating less medical waste, which contributes to reduced disposal costs and a smaller environmental footprint.

State Of The Art

Manufacturing Plant

Harsh Mehta

Harsh Mehta

Head Of International BD

Our Patent Holders

Pramod Kumar

Pramod Kumar

Production Manager

Reactions

Buzz on WHO Prequalification

“Our successful WHO Prequalification for the early activation auto-disable syringe marks a significant milestone in our commitment to healthcare excellence. This recognition validates our syringe’s rigorous adherence to stringent international standards, ensuring its efficacy, safety, and reliability in diverse healthcare settings globally.”

Rajni Vora

Chairman and Founder, Revital Healthcare EPZ Ltd
“Revital’s historic WHO pre-qualification for the early-activation AD syringe exemplifies the transformative power of African innovation and manufacturing excellence. Our commitment to the well-being of our fellow people, especially children receiving life-saving immunization, is our motivation to continue to progress.”

Roneek Vora

Director of Marketing and Sales, Revital Healthcare EPZ Ltd
“I am thrilled by our achievement of WHO Prequalification for the early activation auto-disable syringe. This accomplishment reflects our dedication to manufacturing precision and the highest quality standards, further solidifying our position as a global healthcare leader, and setting new benchmarks for innovation in medical device manufacturing.

Ankur Vora

Director of Operations, Revital Healthcare EPZ Ltd

Blog

Latest News & Resources

Revital Healthcare Shines in The New York Times

Revital Healthcare Shines in The New York Times

FeaturedRevital Healthcare Shines in The New York TimesRevital Healthcare is featured in The New York Times for its impactful contributions to Africa's healthcare self-reliance. Our story, as highlighted by The New York Times, is one of resilience, innovation, and...

Africa’s Largest Rapid Test Kit Production Facility

Africa’s Largest Rapid Test Kit Production Facility

Press ReleaseRevital Healthcare’s Largest Rapid Test Kit Production Facility in Africa launched by U.S. Ambassador Meg WhitmanRevital Healthcare proudly stands as Africa's premier manufacturer of rapid test kits, leading the region in healthcare innovation.Official...

Revital banks blanket contract from a key global organisation

Revital banks blanket contract from a key global organisation

Blog News &UpdatesRevital Healthcare banks blanket contractfrom a key global organisationRevital Healthcare has recently secured a notable contract with a global organization to supply India with 50 million units of 2ML vaccine syringes amidst concerns over a...